Literature DB >> 7635870

Reversal of multidrug resistance by novel cyclosporin A analogues and the cyclopeptolide SDZ 214-103 biosynthesized in vitro.

K Schwabe1, G Steinheider, A Lawen, R Traber, A Hildebrandt.   

Abstract

It was shown that cyclopeptolide SDZ 214-103 (10 microM) is more active in rhodamine-123 accumulation in actinomycin-D-resistant human lymphoma cells CCRF/ACTD400 than cyclosporin A (10 microM), but equipotent in the doxorubicin-resistant Friend erythroleukemia cell line F4-6/ADR. In F4-6/ADR cells, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay showed comparable cytotoxic effects of doxorubicin at various concentrations in the presence of SDZ 214-103 and cyclosporin A. For the other novel cyclosporin A analogues minor multidrug-resistance-modulating potency was demonstrated. At equipotent modulating doses of verapamil (10 microM) and cyclosporin A (10 microM) in the MTT assay regarding doxorubicin cytotoxicity, cyclosporin A was efficient in the rhodamine-123-uptake assay while verapamil was not active when identical incubation times were used.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7635870     DOI： 10.1007/bf01212947

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


  23 in total

1.  Derivatives of a novel cyclopeptolide. 2. Synthesis, activity against multidrug resistance in CHO and KB cells in vitro, and structure-activity relationships.

Authors:  G Emmer; M A Grassberger; G Schulz; D Boesch; C Gavériaux; F Loor
Journal:  J Med Chem       Date:  1994-06-24       Impact factor: 7.446

2.  Cyclosporin synthetase. The most complex peptide synthesizing multienzyme polypeptide so far described.

Authors:  A Lawen; R Zocher
Journal:  J Biol Chem       Date:  1990-07-05       Impact factor: 5.157

3.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

Authors:  F Hyafil; C Vergely; P Du Vignaud; T Grand-Perret
Journal:  Cancer Res       Date:  1993-10-01       Impact factor: 12.701

4.  In vitro and in vivo comparative studies on immunosuppressive properties of cyclosporines A, C, D and metabolites M1, M17 and M21.

Authors:  N Sadeg; C Pham-Huy; P Rucay; S Righenzi; O Halle-Pannenko; J R Claude; H Bismuth; H T Duc
Journal:  Immunopharmacol Immunotoxicol       Date:  1993 Mar-Jun       Impact factor: 2.730

5.  SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells.

Authors:  A Pourtier-Manzanedo; A D Didier; C D Muller; F Loor
Journal:  Anticancer Drugs       Date:  1992-08       Impact factor: 2.248

6.  Cell-free biosynthesis of new cyclosporins.

Authors:  A Lawen; R Traber; D Geyl; R Zocher; H Kleinkauf
Journal:  J Antibiot (Tokyo)       Date:  1989-08       Impact factor: 2.649

7.  Reversal of resistance to rhodamine 123 in adriamycin-resistant Friend leukemia cells.

Authors:  T J Lampidis; J N Munck; A Krishan; H Tapiero
Journal:  Cancer Res       Date:  1985-06       Impact factor: 12.701

8.  mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles.

Authors:  V Gekeler; S Weger; H Probst
Journal:  Biochem Biophys Res Commun       Date:  1990-06-15       Impact factor: 3.575

9.  In vitro biosynthesis of peptolide SDZ 90-215 by a 1.2 MDa multienzyme polypeptide.

Authors:  C Lee; A Lawen
Journal:  Biochem Mol Biol Int       Date:  1993-12

10.  SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.

Authors:  F Loor; D Boesch; C Gavériaux; B Jachez; A Pourtier-Manzanedo; G Emmer
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.